Key facts
- BioLoomics’s last known valuation is $22.4M (Mar 2023).
- It has raised $10.4M across 4 recorded rounds; the latest was Seed Round ($450K) in Aug 2025.
- Notable investors include Innovation Endeavors, Horizons Ventures, Hummingbird Ventures, BoxOne Ventures, Ms2 Capital — 12 tracked in total.
- BioLoomics has filed 3 Form Ds with the SEC since 2019, most recently Mar 2023 ($9.3M sold to 23 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for BioLoomics
Funding rounds
4 roundsAbout BioLoomics
Developer of antibody-based therapeutics designed for enhanced drug delivery in oncology. The company's platform integrates membrane-binding peptides into antibody drug conjugates, leveraging advanced bioinformatics, AI-driven peptide design, and high-throughput screening to optimize membrane loading, internalization, and cytotoxicity, enabling pharmaceutical researchers to improve targeted drug efficacy, reduce off-target effects, and enhance therapeutic outcomes in cancer treatment
- Sector
- Healthcare
- HQ
- Boulder, CO, United States
- Founded
- 2019
- Employees
- 16
- Website
- bioloomics.com/
- Ownership
- Privately Held (backing)
BioLoomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioLoomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioLoomics in its N-PORT filings yet. We sweep new filings monthly.